Cancer
J&J under fire from 170 nonprofits to halt baby powder sales worldwide because it contains asbestos
July 9, 2020Sales and Marketing Cancer, J&J, JJ, pharma, talc
In the latest chapter in Johnson & Johnson’s talc-related woes, the company is being pressured by group of over 170 …
European green light for Lynparza in germline BRCA-mutated metastatic pancreatic cancer
July 8, 2020Research and Development, Sales and Marketing AstraZeneca, Cancer, Europe, MSD, lynparza
The European Commission has awarded approval to AstraZeneca and MSD’s Lynparza (olaparib) for germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer, with …
COVID-19 impact on England’s cancer services could lead to 35,000 excess deaths
July 8, 2020Research and Development COVID-19, Cancer, England, coronavirus
New data emerging from DATA-CAN: The Health Data Research Hub for Cancer has shone a light on the potential toll …
FDA approval for Jazz and PharmaMar’s Zepzelca in metastatic small cell lung cancer
June 17, 2020Manufacturing and Production, Research and Development, Sales and Marketing Cancer, FDA, PharmaMar, Zepzelca, jazz pharma, lung cancer
The FDA has awarded approval to Jazz Pharma and PharmaMar for Zepzelca (lurbinectedin) as a treatment for metastatic small cell …
Gilead’s magrolimab shows promising responses in untreated myelodysplastic syndrome and acute myeloid leukaemia at ASCO 2020
June 1, 2020Research and Development, Sales and Marketing ASCO 2020, Cancer, Gilead, leukaemia, magrolimab
Gilead took the opportunity at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting to unveil new Phase 1b …
Lynparza secures CHMP recommendation in first-line BRCA-mutated metastatic pancreatic cancer
June 1, 2020Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza
Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has just secured recommendation for approval from the European Medicines …
Lynparza combo authorised in US for first-line maintenance of HRD-positive advanced ovarian cancer
May 11, 2020Sales and Marketing AstraZeneca, Cancer, MSD, lynparza, ovarian cancer
Lynparza (olaparib), developed by AstraZeneca and MSD, has secured FDA approval when paired with bevacizumab as a first-line maintenance treatment …
NICE gives thumbs-up to Roche’s Kadcyla in HER2+ breast cancer sub-population
May 7, 2020Sales and Marketing Cancer, Kadcyla, NHS, NICE, Roche, UK, breast cancer
NICE has revealed that it has recommended the NHS use of Roche’s Kadcyla (trastuzumab emtansine) for HER2+ breast cancer in …
Sanofi and Regeneron’s Libtayo shows durable responses in world’s most common skin cancer
May 5, 2020Manufacturing and Production, Research and Development Cancer, Libtayo, Regeneron, Sanofi
Sanofi and Regeneron’s have lifted the lid on new topline data on their PD-1 inhibitor Libtayo (cemiplimab) in patients with …
Phase 3 Libtayo monotherapy trial halted early due to strong benefit in advanced non-small cell lung cancer
April 29, 2020Research and Development Cancer, Libtayo, Regeneron, Sanofi, lung cancer
A Phase 3 study of Sanofi and Regeneron’s Libtayo (cemiplimab) as a monotherapy for advanced or metastatic non-small cell lung …
FDA approves Immunomedics’ Trodelvy for metastatic triple-negative breast cancer one month ahead of schedule
April 23, 2020Sales and Marketing Cancer, Immunomedics, Trodelvy, breast cancer, pharma
Immunomedics has scored approval with the FDA for Trodelvy (sacituzumab govitecan-hziy) in the treatment of metastatic triple-negative breast cancer, it …
AbbVie’s Imbruvica scoops up 11th FDA approval with chronic lymphocytic leukaemia/small lymphocytic lymphoma nod
April 22, 2020Research and Development, Sales and Marketing Cancer, FDA, imbruvica, leukaemia
AbbVie’s Imbruvica (ibrutinib) has scored its 11th FDA approval, this time in combination with rituximab for the treatment of chronic …
Bayer’s Vitrakvi becomes first tumour-agnostic therapy approved by NICE for NHS patients with NTRK fusion+ cancer
April 21, 2020Manufacturing and Production, Sales and Marketing Bayer, Cancer, NICE, UK, Vitrakvi, tumour agnostic
Bayer’s oral TRK inhibitor Vitrakvi (larotrectinib) has just been recommended by NICE in the treatment of advanced neurotrophic tyrosine receptor …
FDA approves UroGen’s Jelmyto as first therapy for low-grade upper tract urothelial cancer
April 16, 2020Sales and Marketing Cancer, FDA, Jelmyto, UroGen Pharma, pharma, urothelial cancer
The FDA has moved to authorise UroGen Pharma’s Jelmyto (mitomycin gel) in the US for the treatment of low-grade upper …
Latest content
Five Facts about cardiovascular disease
